As intracardiac thrombus is often associated with diseases involving the endocardium and/or myocardium of the left ventricle, the precise prevalence of left ventricular thrombus is difficult to ascertain. For example, the presence of intracardiac thrombus has been associated with many diseases and clinical states (box 1), although cardiac impairment is also commonly present and associated with stroke and thromboembolic risk.'
The commonest cause of cardiac impairment in clinical practice remains ischaemic heart disease. However, there continues to be a lack of consensus on which patients with cardiac impairment should have anticoagulant therapy. This is due to the perceived lack of evidence, the uncertainty of diagnosis (especially of intracardiac thrombus) and the inconvenience and safety aspects of using warfarin. The diagnosis of intracardiac thrombus is further influenced by changes in imaging techniques and management strategies for different cardiac problems.
Mechanisms and factors contributing to thromboembolism
It has long been recognised that thromboembolism is a frequent cause of death in patients with congestive heart failure, occurring in up to 30% of patients.2 Despite the high incidence in some series, anticoagulant therapy has not been widely used as an adjuvant to routine therapy in patients with cardiac impairment. This may be due to the fact that there has not been a controlled trial assessing the efficacy of anticoagulation in patients with heart failure secondary to cardiac impairment outside the hospital setting.
Most data on intracardiac thrombus formation and thromboembolism have been related to cardiac impairment in association with left ventricular aneurysms. For example, the frequency of left ventricular thrombi in aneurysms seen at post mortem can range between 14 to 68%, which is consistent with findings at aneurysmectomy (50_95%).1 However, the reported incidences of systemic thromboembolism in patients with left ventricular aneurysm demonstrate a wide range, from 0 to 52%. 1, [3] [4] [5] Thus, although it is generally considered that patients with chronic aneurysms (longer than three months) are at low thromboembolic risk, a high proportion still have intracardiac thrombus formation. There is thus some debate on the likelihood of thromboembolism.1
In patients with heart failure, post acute myocardial infarction and cardiomyopathy, most studies have depended upon echocardiographic detection of thrombus. In a recent review, the incidence of arterial thromboembolic events in patients with heart failure ranged from 0.9 to 42.4 events per 100 patient-years, equivalent to an annual incidence of thromboembolism or stroke in patients with heart failure of approximately 1.9%.6 However, the prevalence of atrial fibrillation in these studies was 12-36%, which may have accounted for some of the thromboembolic events,6
Thromboembolism and stroke are also common complications in cardiac dysfunction secondary to cardiomyopathy. For example, the incidence of thromboembolic stroke in hypertrophic cardiomyopathy has been reported to be 3% per patient year, which is increased by the presence of atrial fibrillation.7'8 Thrombus has also been found in approximately 36% of patients with chronic dilated cardiomyopathy on two-dimensional echocardiography.9
Systemic emboli occurred in 1 1 % of these patients, but there was no difference in the incidence of emboli when compared to those with no thrombus visualised at echocardiography.9 Falk et may be due to the likelihood of thromboembolism of cardiac thrombi, which is dependent upon many different factors, as discussed below (box 2).
MECHANICAL AND FLOW ABNORMALIES IN CARDIAC IMPAIRMENT
Low cardiac output, aberrant flow through dilated cardiac chambers and poor contractility may all predispose to intracardiac thrombus formation and subsequent thromboembolism. In a left ventricular aneurysm, for example, there is both diastolic and systolic bulging or asynergy, resulting in severe stasis of blood, with consequent predisposition towards thrombus formation. Poor systolic function may also cause stasis of blood within a dilated left ventricular cavity (with or without aneurysm formation).11 There is also evidence that the embolic potential of left ventricular thrombus may be directly related to the presence of adjacent segments of normally functioning myocardium (with altered flow characteristics) and inversely related to the stability of the thrombus. For example, in an echocardiographic study of 40 patients with cardiomyopathy, there were specific abnormally low flow profiles at the ventricular apex associated with the presence of left ventricular tbrombus.12 Similar abnormal flow profiles have been demonstrated by pulsed Doppler echocardiography in patients post myocardial infarction who subsequently develop intracardiac thrombus. 3 In this latter study, the abnormalities were evident in diastole, suggesting that the absence of diastolic recoil of the apex of the heart was additive to the impaired systolic contraction in creating disturbed flow patterns.
Interestingly, in the cardiomyopathy patients without intracardiac thrombus, there was a higher prevalence of mitral regurgitation despite abnormal Doppler flow profiles.'2 The presence of mitral regurgitation may therefore serve as a protective factor against thrombus formation as the higher inflow velocities may result in a lower tendency for thrombus formation. The findings of these two studies therefore suggest that flow abnormalities are important in promoting thrombogenesis in patients with cardiac impairment, and that Doppler echocardiography may be useful in patient risk stratification by the identification of a high risk group (with abnormal flow patterns), who would benefit from prophylactic anticoagulation. ' dimer (a marker of fibrin turnover and thrombogenesis'9) and von Willebrand factor levels (a marker of endothelial dysfunction20). These abnormalities were primarily due to systolic or contractile dysfunction, with little contribution from diastolic dysfunction, and were normalised by warfarin.'8'21 Another study by Jafri et a122 found that, regardless of the aetiology, patients with heart failure show significant abnormalities of platelet activation (as reflected by platelet factor 4 and beta-thromboglobulin), and markers of haemostasis such as thrombin-antithrombin 4 complex (TAT4), fibrinopeptide A and fibrin Ddimer. Abnormalities of haemostasis were also shown by Sbarouni Two-dimensional echocardiography may also have disadvantages in visualising the left ventricular apex for characteristic wall thinning and possible apical thrombus formation (seen in aneurysm formation), as the sector angle is 90 degrees and the apex is usually too near the probe in the four-chamber view.32
Overall cardiac motion towards the apex in systole also tends to accentuate apical dyskinesis and to obscure inferoposterior wall dyskinesia.14 Axial and lateral resolution problems can also produce intracavity echoes that may mimic thrombi. For example, normal or pathologic structures at the apex that may simulate thrombi include the papillary muscles, chordal structures and tangential information from normal myocardium. A final limitation of echocardiography is its inability to reflect thrombus activity, that is, whether or not ongoing thrombogenesis is present. It is useful, however, in quantifying thrombus size and mass.
Transoesophageal echocardiography is a recent advance in improving imaging of intracardiac thrombi. This technique is of particular value in patients who are poor subjects for transthoracic echocardiography, and if metal valve prostheses are present. Although the true sensitivity of transoesophageal echocardiography for detecting intracardiac thrombi is unknown, but it is likely to be related to the size of the thrombus and the ability to obtain adequate imaging of the heart. Radionuclide studies may be useful in providing information on the degree of cardaic impairment and the presence of aneurysms. For example, equilibrium gated radionuclide ventriculography, employing 99m-technetium, is useful as an objective measure of left ventricular function. It also allows assessment of wall motion abnormalities, particularly by the study of phase and amplitude images.
Experimental studies have reported the use of radionuclide techniques in the detection of left ventricular thrombus. In addition, one useful radionuclide method of identifying left ventricular thrombus employs indium-i1 1 platelet scintigraphy.28 '33 This has a specificity of 100% and sensitivity of 71%, which is even greater than that of echocardiography.8'34 One further advantage of this method is its ability to assess the surface activity of the thrombus, and thus complement echocardiographic assessment. The use of indium-i 11 platelet scintigraphy may therefore be particularly helpful in identifying patients with chronic left ventricular thrombi at increased risk of embolisation. In one study, embolisation occurred in 23% ofpatients with a positive platelet scintigram and echocardiogram, compared with only 4% of patients with a negative platelet scintigram but positive echocardiogram.'7 This method may therefore detect 'active' thrombi, which are at high risk of embolisation. However, platelet scintigraphy is essentially only available in specialist centres and is not widely available in clinical practice.
OTHER TECHNIQUES
Left ventricular contrast cineangiography may be useful for the diagnosis of significant wall motion abnormalities, including the presence of a left ventricular aneurysm. However, the investigation is less useful for the diagnosis of mural thrombus with a reported sensitivity of 31%, a specificity of 75% and a predictive accuracy of only 54%.35 There is also the risk of dislodging mural thrombus (if present) and causing systemic thromboembolism by the procedure.
Other useful techniques for the investigation of left ventricular function and thrombus include magnetic resonance imaging32'36 and computed tomography,37 but these techniques are limited to a few centres. Contrary to expectation, the introduction of thrombolytic therapy (streptokinase or recombinant tissue plasminogen activator) in the acute management of patients with anterior myocardial infarction does not appear to reduce the risk of left ventricular thrombus formation.27 Few data exist on whether early intervention with coronary angioplasty may reduce the risk of subsequent left ventricular thromboembolism.
group.bmj.com on October 20, 2017 -Published by http://pmj.bmj.com/ Downloaded from Thus, following a large acute anterior myocardial infarction, especially if severe cardiac impairment is present, patients should be considered for full anticoagulation with heparin, followed by warfarin, in the absence of contraindications.
LEFT VENTRICULAR ANEURYSM
The definition of what a left ventricular aneurysm is remains controversial and may vary considerably between different studies and with different investigational methods. 45 Obviously, if definitions vary from study to study, the results or conclusions may do likewise; this may make some comparisons between the studies difficult to interpret.
It is generally accepted that the presence of a left ventricular aneurysm may have significant haemodynamic consequences. This includes the reduction in stroke volume and ejection fraction, and the presence of life-threatening arrhythmias. All of these changes may result in increased susceptibility to congestive heart failure, with important implications for patient survival. 46 Overall, the incidence of left ventricular aneurysm following myocardial infarction is about 7 to 10%, and surgical, autopsy and echocardiographic studies indicate that about half of all patients, with post-infarction ventricular aneurysm, have mural thrombus present.27'38'45 However, mural thrombus does appear to occur more frequently in the presence of an aneurysm.5 In an overview of six studies (mean follow-up periods of 6 to 15 months), Sherman et at47 reported that late emboli occurred in only 1% of 98 anticoagulated patients, compared to 13% of 46 non-anticoagulated patients. It is also usually accepted, therefore, that the identification of mural thrombus in patients with left ventricular aneurysm warrants long-term oral anticoagulation as part of any medical management strategy. 35'3947 It is also argued, however, that in chronic left ventricular aneurysms diagnosed at least six months after myocardial infarction, mural thrombus is common but the risk of embolism is low (an incidence of 0.35 per 100 patientyears) and that anticoagulation may not be warranted.3'1145 One echocardiographic study reported that the presence of thrombi at six months follow-up was the same regardless of anticoagulant treatment.38 In addition, two surgical studies showed no apparent effect of anticoagulation on the prevalence of mural thrombus identified at aneurysmectomy.35'48 The duration of anticoagulant therapy correlates inversely with the presence of thrombus, and this may account for the discrepancy in these findings of the benefits of anticoagulants. 35 Thus, despite the associated theoretical increase in thromboembolic risk by the presence of a thrombus in a left ventricular aneurysm, there is some evidence that these thrombi may only rarely embolise. 27 The precise reasons for this are unclear, but (as discussed earlier) the haemodynamic effects of left ventricular dysfunction or aneurysm may contribute to any altered thromboembolic risk in such patients. Aneurysm expansion may thus result in progressive haemodynamic deterioration with increasingly impaired left ventricular function.
The role of preventive strategies against thromboembolism in patients with left ventricular aneurysms therefore remains controversial, since the haemodynamic status of the patient may continue to alter with time. Nevertheless, anticoagulant therapy is recommended, at least in the initial period (3-6 months), after diagnosis of a left ventricular aneurysm, especially if intracardiac thrombus is present.
CHRONIC HEART FAILURE
The use of warfarin therapy in patients with chronic heart failure in routine clinical practice is uncommon. In a recent survey of patients acutely admitted with heart failure to our hospital, warfarin therapy was only prescribed to 19% (Lip GYH et al, submitted for publication). This is despite evidence that warfarin therapy may be beneficial in reducing the risk of thromboembolism and stroke in some subgroups of patients with heart failure.
For example, in one early study of 390 patients, there was a significant reduction in the incidence of thromboembolism in patients with chronic heart failure, especially in those with coexisting rheumatic heart disease, by the use of warfarin. There was also a reduction in mortality by 5.8% (to 8%), with a 6-9%/. reduction in the incidence of thromboemboli. ventricular apical wall motion with the early use of beta-blocker therapy may actually increase the risk of thrombus formation.49 A recent review by Baker et a16 reported that efficacy of anticoagulation in case series ranged from 0 to 100%. Warfarin therapy has however been associated with higher resolution of thrombus at echocardiography in patients with chronic heart failure when compared to patients on no therapy (59% vs 29%, respectively).16 Two controlled trials from almost 50 years ago also reported a decreased incidence of pulmonary thromboembolism in hospitalised patients treated with anticoagulants.50'5' However, if heart failure is only mild or moderate (NYHA Grade II and III), recent evidence from the V-HeFT study suggests that the incidence of thromboembolism or stroke is not high, with little benefit from warfarin therapy. 52 The results from the V-HeFT study should be viewed with some caution as the study was not initially designed to investigate the benefits of antithrombotic therapy and the therapeutic level of anticoagulation was not routinely monitored as part of study protocol.
Thus, routine use of anticoagulants in patients with heart failure, unless severe, may not be justified. Furthermore, no controlled trial has fully assessed the efficacy or risks of anticoagulation for ambulant patients in heart failure and sinus rhythm in the outpatient setting.
ATRIAL FIBRILIATION AND LEFT VENTRICULAR DYSFUNCTION
The presence of heart failure or ventricular impairment is known to be additive to the risk of thromboembolism in patients with atrial fibrillation. The situation is therefore far from clear -just who is at risk of thromboembolism? Although warfarin will prevent stroke and other thromboembolic events, there is (at present) no easy way to stratify patients with heart failure for baseline risk and potential benefit. Suggested guidelines for initiating anticoagulant therapy in patients with left ventricular thrombi are summarised in box 4. Based on current evidence, patients sustaining a large anterior myocardial infarction with poor cardiac function, atrial fibrillation and a protruding, mobile left ventricular thrombus are at highest risk, requiring anticoagulant therapy. If patients are in sinus rhythm, anticoagulants should perhaps be reserved, especially for patients with severe cardiac impairment, the presence of intracardiac thrombus, and previous thromboembolism or stroke. Thus, until guidelines become available, clinical decisions to treat patients with cardiac impairment with anticoagulants must be made on an individual basis, based upon individual benefits and risks.
Conclusion
Warfarin has been established as thromboprophylaxis in certain subgroups of patients with cardiac impairment secondary to ischaemic heart disease. The evidence for aspirin as adequate thromboprophylaxis against thromboembolism and stroke in patients with cardiac impairment in sinus rhythm remains limited. A large-scale randomised controlled trial in ambulant patients with heart failure to evaluate the effectiveness of anticoagulant therapy and antiplatelet therapy is, however, long overdue. Nevertheless, the identification of patients with cardiac impairment who are at greatest risk of systemic embolisation is of particular importance -echocardiography and/or radionuclide studies are useful investigations for this purpose.
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